The leukemia drug Icusig that was given rapid approval by the FDA in December 2012 is now off the market and clinical trials are halted. The FDA received an alarming number of reports of more than a dozen deaths and a still-to-be-counted tally of serious injury from blood clots, heart attack, stroke, lack of blood to the extremities leading to tissue death and more.
What started as a good intention, to quickly approve a drug to help patients who weren’t responding to the standard leukemia treatments, has had dire consequences. While the drug’s “fast track” may have benefitted some patients, others who received the drugs from their doctors as well as those in post-approval clinical trials have been affected.
The FDA says in several news articles that the only relief for the injured is surgery.
If you or someone you know is taking or has taken Icusig (ponatinib), contact your doctor immediately to discuss your treatment. Some patients experienced significant side effects two weeks after starting the drug.
The defective drug attorneys at Harman Law LLC are available for comment or questions from patients, physicians and the media. The firm is investigating this drug on behalf of patients who may have been harmed
Iclusig is made by Ariad Pharmaceuticals.
Posted on behalf of
